Meloxidolor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meloxidolor

Property Description
Active ingredient Meloxicam
Form Injectable Solution, Oral Suspension
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use Relief of inflammation, pain, and fever
Origin Synthetic Compound

What Type of Medicine is Meloxidolor? (NSAID Classification and Origin)

Meloxidolor is a specific veterinary medicinal product containing the single active ingredient, Meloxicam. This compound is classified within the broad group of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and chemically belongs to the oxicam family. The active substance is a synthetic compound that is clinically recognized for its anti-inflammatory properties. The drug is pharmacologically defined by its core identity as a preferential Cyclooxygenase-2 (COX-2) inhibitor.

Meloxicam: Composition and Drug Form

Meloxidolor utilizes Meloxicam as its only active substance, defining it as a single-ingredient product. The medicine is supplied in various pharmaceutical preparations, primarily as an injectable solution for parenteral delivery, which is formulated as an aqueous-alcoholic solution for systemic absorption. This initial injection form is frequently followed by an oral suspension of Meloxicam for continuation of treatment.

General Purpose: Relief of Pain and Inflammation

The medicine’s purpose is to provide symptomatic relief by exhibiting anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) effects. This triple action is the direct result of the compound’s core mechanism: the inhibition of prostaglandin synthesis. The drug is effective in managing painful and inflammatory symptoms, supporting its use in cases of acute or chronic discomfort. The drug's action is typically applied in scenarios involving acute pain or chronic inflammatory issues, such as those arising from musculoskeletal disorders.

What side effects are possible with Meloxidolor?

Possible Side Effects and Safety Information

Meloxidolor is a non-steroidal anti-inflammatory drug (NSAID) and carries the characteristic safety profile of this drug class, primarily involving risks to the gastrointestinal (GI) and renal systems. All reported adverse reactions should prompt discontinuation of use.

Adverse Reactions Summary

System-Organ Class Frequency Examples of Reported Reactions
Gastrointestinal Rare Loss of appetite, vomiting, diarrhea, lethargy, occult blood in faeces.
Serious GI Events Very Rare Haemorrhagic diarrhea, haematemesis, gastrointestinal ulceration.
Systemic/Renal Rare Renal failure.
Systemic/Other Very Rare Elevated liver enzymes, anaphylactic reactions (can be serious or fatal).

Note: Adverse reactions are typically observed within the first week of treatment and are often transient.

Safety Restrictions and Contraindications

Meloxidolor must not be used in the following circumstances:

  • In animals with known hypersensitivity to the drug or other NSAIDs.
  • In animals suffering from existing gastrointestinal disorders (such as irritation or hemorrhage), impaired hepatic, cardiac, or renal function, or haemorrhagic disorders.
  • Concurrently with other NSAIDs or glucocorticosteroids (e.g., cortisone), as this significantly increases the risk of severe side effects.

Use should be avoided in any dehydrated, hypovolaemic, or hypotensive animal due to a potential risk of kidney toxicity. Special precautions are required for pregnant women or women of child-bearing potential due to the potential harm to the foetus and unborn child from exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Meloxicam (Meloxidolor) documents the specific clinical signs and required emergency actions in case of overdose. This information is provided for guidance and requires professional medical interpretation.

Overdose presentations are generally categorized from milder gastrointestinal effects to severe systemic outcomes. Initial documented manifestations include lethargy, nausea, vomiting, and epigastric pain.

Potential Severe Outcomes (Documented) Management Requirements (Documented)
Acute renal failure No specific antidote is known
Hepatic dysfunction Symptomatic and supportive treatment
Respiratory depression Hospital monitoring is required
Anaphylactoid reactions Monitoring of renal and liver function

Immediate medical attention must be sought for any suspected overdose. The risk of severe, life-threatening complications, such as coma or cardiac arrest (in rare, massive overdose cases), necessitates immediate contact with emergency services. Due to the lack of an antidote, official guidance directs management toward supportive care, including the potential use of activated charcoal and continuous hospital observation to stabilize the patient.

Therapeutic Uses of Meloxidolor

Managing Symptoms of Chronic Joint Conditions

Meloxidolor is commonly used to help with symptoms related to physical discomfort, such as pain, swelling, and stiffness, associated with chronic inflammatory conditions. It is applied in situations involving symptomatic discomfort and is commonly used to help with signs and symptoms of major indications including osteoarthritis (OA) and rheumatoid arthritis (RA). It supports patients during episodes of heightened discomfort, which contributes to improved day-to-day comfort and supports general well-being during symptomatic phases.

“The medication is relevant when supportive symptom management is appropriate, particularly when symptoms create noticeable physiological strain.”


Easing Acute Pain Flares and Post-Surgical Discomfort

The medication is also applied in contexts where additional support for short-term symptomatic management is needed, such as during phases when symptoms may intensify temporarily or following surgical procedures. It is used in settings where short-term symptomatic assistance is needed. This assists with maintaining functional stability when symptoms become more noticeable.

Quick Fact: Relief for Musculoskeletal Pain


Supporting Functional Mobility and Comfort

Across all uses, the key therapeutic benefit is addressing symptoms that create noticeable interference with daily functioning and routine activities. By addressing these symptoms, Meloxidolor provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH DailyMed Meloxicam Label

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Meloxidolor

Eligibility for Meloxidolor (Meloxicam) is determined by official regulatory criteria, focusing on age, reproductive status, and pre-existing health conditions. Use is strictly governed by prohibitions and restrictions defined in regulatory documents.


Who Must Not Use This Medicine (Contraindications)

This medicine is contraindicated and must not be used by individuals with:

  • Known Hypersensitivity: A history of allergy to Meloxicam, Aspirin, or any other NSAID.
  • Severe Organ Impairment: Diagnosed severe hepatic impairment or severe, non-dialysis dependent kidney disease.
  • Gastrointestinal Risk: Active peptic ulceration or a documented history of GI ulceration complicated by hemorrhage or perforation.
  • Late Pregnancy: Females who are 30 weeks gestation or later (Third Trimester).
  • Peri-operative Pain: Treatment of pain after Coronary Artery Bypass Graft (CABG) surgery.

Age and Reproductive Status Eligibility

Population Official Eligibility Status
Adults (18+), General Approved for symptomatic treatment of Osteoarthritis and Rheumatoid Arthritis.
Children 2 to 17 Years Approved only for Juvenile Idiopathic Arthritis (JIA). Use for other conditions is not established.
Pregnant Patients Contraindicated from 30 weeks gestation onward. Limited use between 20 and 30 weeks.
Older Adults (65+) Use is permitted but requires caution due to a higher risk of adverse effects.

Condition-Based Restrictions

Use requires caution or is not recommended in patients with a history of cardiovascular conditions (e.g., uncontrolled heart failure or hypertension) and must be preceded by correction of conditions like dehydration or hypovolemia.

What should I know about interactions with other medicines?

Meloxidolor Interactions with other medicines and products

Meloxidolor, containing Meloxicam, has officially documented interaction patterns primarily involving pharmacodynamic and exposure-modifying effects with certain medicinal products.

Contraindicated Combinations

Classification Restricted Substances Regulatory Basis
Formal Contraindication Aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (in patients with documented hypersensitivity to these agents). FDA/ EMA Labeling
Procedural Restriction Use for peri-operative pain management in the setting of Coronary Artery Bypass Graft ( CABG) surgery. FDA Labeling

Clinically Significant Interactions

Co-administration with Warfarin or Selective Serotonin Reuptake Inhibitors ( SSRIs) increases the risk of bleeding complications due to additive anti-hemostatic effects. Combining Meloxicam with other NSAIDs or Corticosteroids is restricted because it creates a synergistic increase in the risk of serious gastrointestinal ulceration and bleeding.

Exposure Modification

Concomitant use with Lithium increases lithium plasma levels potentially to toxic concentrations. Similarly, Meloxicam increases the plasma concentration of Methotrexate, enhancing its potential toxicity.

Renal Hemodynamic Interactions

Meloxicam may reduce the natriuretic effect of Diuretics and diminish the antihypertensive effect of Angiotensin-Converting Enzyme ( ACE) Inhibitors or Angiotensin Receptor Blockers ( ARBs). This interaction, which may result in renal function deterioration, is noted in the regulatory documents as having heightened significance in elderly, volume-depleted, or renally impaired patients.

Mechanism of Action

How Meloxidolor Works

The mechanism of Meloxidolor (Meloxicam) is defined by its highly targeted interference with a core biological signaling cascade.


Molecular Inhibition of the COX-2 Enzyme System

The drug's primary action is the preferential inhibition of the Cyclooxygenase-2 ( COX-2) enzyme. COX-2 is an inducible enzyme largely responsible for synthesizing key biological mediators from the arachidonic acid cascade. By blocking COX-2 activity, the drug selectively suppresses the production of these mediators.


Disrupting the PGE2 Signaling Cascade

The inhibition of COX-2 causes a critical reduction in the synthesis of Prostaglandin E2 ( PGE2), a key biological mediator involved in nociceptive and vascular signaling. This targeted reduction modifies the chemical environment of peripheral nociceptors.


Modulation of Central Thermoregulatory Signaling

The same mechanism affects PGE2 synthesis within the brain’s hypothalamus, which is the body’s central control point for temperature. By suppressing PGE2 production in this area, the drug influences the central mechanism that controls the body’s temperature set-point, leading to an adjustment of that set-point.

Dosage and Administration Information

Official Administration Guidelines

The use of Meloxidolor (meloxicam) must strictly follow the lowest effective dosage for the shortest duration possible, consistent with individual treatment goals. The drug is administered once daily via oral or intravenous (IV) routes.

Dosing and Route of Administration

Administration Route Adult Starting Dose Adult Maximum Daily Dose Frequency
Oral (Tablet/Suspension) 7.5 mg once daily 15 mg once daily Once daily
Intravenous (IV) 30 mg bolus injection 30 mg bolus injection Once daily

For adult patients on hemodialysis, the maximum recommended daily oral dosage is limited to 7.5 mg.

Procedural Steps and Timing

  • Oral Forms: Tablets and oral suspension may be taken without regard to the timing of meals. Oral suspension must be shaken gently before use.
  • Intravenous Forms: The 30 mg IV dose is administered as a bolus injection over 15 seconds. Patients must be well hydrated prior to IV administration.
  • Missed Dose: If a dose is missed, it should be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped; do not take a double dose.

Pediatric Use Rules

For Juvenile Rheumatoid Arthritis (JRA), the recommended oral dose of the suspension is 0.125 mg/kg once daily, up to a maximum of 7.5 mg, for children 2 years of age and older. Dosing for children weighing less than 60 kg should use the oral suspension form to improve accuracy. Tablets (7.5 mg or 15 mg) are generally for children weighing 60 kg or more.

Recent Clinical Evidence

Research evidence / Overview of Studies for Meloxidolor

The research base for Meloxidolor’s active substance, Meloxicam, is built on controlled scientific studies and regulatory analyses. Research examined outcomes related to physical discomfort in various conditions. The evidence is derived from clinical trials, systematic reviews, and meta-analyses referenced by regulatory or major guideline bodies.


Evidence for Chronic Joint Conditions (Osteoarthritis and Rheumatoid Arthritis)

Research for chronic joint conditions, such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA), is primarily derived from Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, comparing the drug to a neutral placebo or to active comparator medicines. Patient-reported experiences were applied in studies examining how individuals felt about changes in pain intensity and physical function, using standardized assessment scales.

The core clinical trials for this compound typically observed responses over defined time intervals spanning 4 to 12 weeks. While the research highlights changes measured during the study period, long-term effects are not fully established beyond a year of observation, and the data quality varies across studies when examining the effect over several months or longer.


Evidence for Acute Pain and Post-Surgical Relief

The evidence for managing acute, severe pain, such as that experienced immediately following surgery, was evaluated in Randomized, Double-Blind, Placebo-Controlled Trials. Research examined the measured outcomes related to opioid consumption and symptom evolution in the first 24 to 48 hours post-procedure. Other study outcomes examined included pain intensity scores and the time elapsed before the patient used rescue analgesia.

Research describes that when the compound was observed in a multimodal pain regimen, studies monitored patterns in opioid consumption and symptom evolution. The treatment protocols observed responses over defined time intervals, usually concluding the primary assessment within 48 hours post-surgery.


What Research Gaps and Uncertainties Remain

One key research limitation is that the primary evidence for acute pain management involves the medicine as a component of a multimodal regimen, meaning the studies primarily examined the combined approach. Additionally, data are still emerging and remain insufficient regarding the evaluation of a single-dose oral formulation in established acute pain episodes. Overall, while research provides insight into short-term changes, the full spectrum of long-term outcomes and effects across all possible patient subgroups is not fully established.

Key Studies & References Label: MELOXICAM tablet - FDA Prescribing Information (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Meloxidolor (FAQ)

Q: What is the main reason doctors prescribe Meloxidolor?

According to the official product information, Meloxidolor is indicated for the symptomatic relief of signs and discomfort associated with certain inflammatory conditions. The main reasons for use include managing the symptoms of chronic joint conditions such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA).

Q: How quickly does Meloxidolor usually start to work?

Official documents on the drug’s pharmacology describe how the body processes the medicine. The time it takes for the drug to reach its peak concentration in the bloodstream—medically known as the Tmax—is typically around 5 to 6 hours after taking an oral dose.

Q: What is the expected duration of action for a dose of Meloxidolor?

The drug's pharmacological properties, including its elimination half-life, are what make it suitable for a once-daily regimen. Official information reports this half-life to be approximately 15 to 20 hours.

Q: Is Meloxidolor safe to take every day for a long time?

Official regulatory guidance states that, like other drugs in its class, Meloxidolor should be used at the lowest effective dosage for the shortest duration possible. Regulatory warnings describe potential risks associated with use that is long-term or prolonged.

Q: Can Meloxidolor be used for muscle pain or stiffness?

Meloxidolor is indicated for specific inflammatory conditions, such as chronic joint pain related to Osteoarthritis and Rheumatoid Arthritis. The drug's regulatory indications focus on these conditions and do not specifically list isolated muscle pain or stiffness as a primary indication for use.

Q: What are the most common side effects listed for Meloxidolor?

Official information from clinical trials indicates that the most commonly reported side effects typically affect the digestive system. These frequently reported adverse events include gastrointestinal complaints such as stomach pain, diarrhea, and feelings of nausea.

Q: Does Meloxidolor cause weight gain or weight loss?

Official documents on side effects do not consistently note weight gain or loss as a frequent adverse reaction. However, edema (swelling), which is related to fluid retention, is listed among potential adverse reactions.

Q: What if I experience unusual swelling while using Meloxidolor?

Swelling, medically known as edema, is listed as a potential adverse reaction in the official product information. The presence of edema may be associated with the drug’s potential for fluid retention, which is a phenomenon documented for medicines in this class.

Q: Can Meloxidolor affect sleep or cause drowsiness?

The official safety profile notes that certain effects on the central nervous system are possible. Regulatory information indicates the possibility of adverse events such as somnolence (drowsiness) and dizziness.

Q: Is it safe to drive or operate machinery after taking Meloxidolor?

Official warnings describe that caution is typically required when performing activities that demand full mental alertness, such as driving or operating machinery. This is due to the potential for certain side effects, like dizziness or drowsiness, that are listed in the regulatory safety documents.

Q: Is it normal to feel a little dizzy when starting Meloxidolor?

Official safety reports list dizziness as an adverse reaction that has been documented as common or frequent in patients taking the medicine.

Q: Are headaches a known side effect of Meloxidolor?

Yes, the official safety reports document that headache is an adverse reaction that has been reported as common or frequent in patients taking the medicine.

Q: Does Meloxidolor have a risk of addiction or dependence?

Regulatory documents indicate that Meloxidolor (meloxicam) is not classified as a controlled substance. The official drug classification indicates that this medicine is not associated with the risk of addiction or dependence.

Q: Is there a generic version of Meloxidolor available?

Official regulatory databases confirm that the active substance in Meloxidolor, which is meloxicam, is widely approved and available in generic formulations.

Q: What are the signs of a serious allergic reaction to Meloxidolor?

Official product information warns that while rare, serious reactions, including anaphylactoid reactions, can occur. Symptoms often described in regulatory documents for these reactions may include difficulty breathing, swelling of the face, throat, or tongue, and severe skin reactions.

Q: Can pregnant or breastfeeding individuals use Meloxidolor?

According to official product labeling, Meloxidolor is contraindicated in the third trimester of pregnancy (30 weeks gestation or later). Safety data regarding its use during breastfeeding is cited as unknown or generally requires caution.

Q: Does alcohol consumption impact the safety profile of Meloxidolor?

Regulatory warnings indicate that consuming alcohol while using the medicine may increase the risk of serious side effects. Specifically, there is an increased risk of potential complications such as gastrointestinal bleeding.

Q: Does Meloxidolor interact with supplements like vitamins or herbal products?

While official regulatory labeling focuses on specific drug-to-drug interactions, it commonly includes a general caution. This guidance clarifies the need for the prescriber to be informed about all other medicines, supplements, or herbal products being used, as potential interactions with these non-prescription items may not be fully evaluated.

Q: Is there a link between Meloxidolor and sunlight sensitivity?

Official post-marketing surveillance documents mention documented instances of adverse events related to photosensitivity. This relates to documented adverse events involving increased skin sensitivity to sunlight (photosensitivity).

Q: How does the body get rid of Meloxidolor (metabolism)?

Pharmacokinetic information describes the process by which the body removes the active substance. The drug is primarily metabolized (broken down) in the liver and is subsequently eliminated from the body through both the urine and feces.

Q: Why is it important to talk to a doctor about my medical history before taking Meloxidolor?

Official warnings detail the need for a complete medical history to be discussed before use. This is due to specific safety risks associated with the drug, requiring conditions like prior gastrointestinal events, cardiovascular disease, or kidney or liver impairment to be accounted for.

How should Meloxidolor be stored and disposed of?

Official Storage and Disposal Requirements

Storage and Protection
Temperature: Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Brief excursions are permitted.
Protection: Keep from freezing, and store away from excessive heat, moisture, and direct light.
Container: Keep the medicine in its original container, tightly closed, and out of the reach of children and pets.
Handling and Disposal
Stability: For liquid forms, check the label for the stability period (e.g., 6 months) after first opening the bottle. Visually inspect injectable products for discoloration before use.
Disposal: Do not flush unused medicine down the toilet or pour it down the sink. The preferred method for disposal is a drug take-back program.
At-Home Disposal: If a take-back program is unavailable, remove the medicine from its original container, mix it with an undesirable substance (like dirt or used coffee grounds), seal the mixture in a plastic bag, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meloxidolor found in:

A-Z Index: